FDA Submission for Dapagliflozin by Sciegen Pharmaceuticals
Sciegen Pharmaceuticals has submitted an original ANDA for Dapagliflozin, currently under standard review.
| Drug | MOA / Company | Stage |
|---|---|---|
| Dapagliflozin | Sciegen Pharmaceuticals | Lead |
Focal Asset
Dapagliflozin
Company
Sciegen Pharmaceuticals
Indication
Diabetes / SGLT2 Inhibitor
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The submission of an ANDA for Dapagliflozin by Sciegen Pharmaceuticals signifies a new entrant in the competitive landscape of SGLT2 inhibitors. This could lead to increased competition, impacting pricing and market dynamics for existing players in the diabetes treatment space.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the review progress and any subsequent approval timelines for ANDA219408.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.